Cargando…
The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome resistance, are urgently needed. The bright expression of the C...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628456/ https://www.ncbi.nlm.nih.gov/pubmed/37941558 http://dx.doi.org/10.3389/fonc.2023.1228481 |
_version_ | 1785131762765004800 |
---|---|
author | Prejzner, Witold Piekoś, Oliwia Bełdzińska, Karolina Sadowska-Klasa, Alicja Zarzycka, Ewa Bieniaszewska, Maria Lewandowski, Krzysztof Zaucha, Jan Maciej |
author_facet | Prejzner, Witold Piekoś, Oliwia Bełdzińska, Karolina Sadowska-Klasa, Alicja Zarzycka, Ewa Bieniaszewska, Maria Lewandowski, Krzysztof Zaucha, Jan Maciej |
author_sort | Prejzner, Witold |
collection | PubMed |
description | Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome resistance, are urgently needed. The bright expression of the CD38 antigen found in several cases of T-ALL led to an investigation into the role of anti-CD38 antibodies in the treatment of T-ALL. Here, we present three cases of resistant and relapsed T-ALL and myeloid/T-cell treated with daratumumab-based therapy, including venetoclax and bortezomib (Dara-Ven-Bor). All patients achieved complete remission, with minimal residual disease negativity within four weeks of treatment, allowing them to proceed to allogeneic hematopoietic cell transplantation. The toxicity of the triple schema was acceptable. Our patients and other cases reviewed here suggest that daratumumab combined with venetoclax and bortezomib may be a very effective and relatively safe salvage treatment, even in primary resistant T-ALL. |
format | Online Article Text |
id | pubmed-10628456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106284562023-11-08 The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review Prejzner, Witold Piekoś, Oliwia Bełdzińska, Karolina Sadowska-Klasa, Alicja Zarzycka, Ewa Bieniaszewska, Maria Lewandowski, Krzysztof Zaucha, Jan Maciej Front Oncol Oncology Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome resistance, are urgently needed. The bright expression of the CD38 antigen found in several cases of T-ALL led to an investigation into the role of anti-CD38 antibodies in the treatment of T-ALL. Here, we present three cases of resistant and relapsed T-ALL and myeloid/T-cell treated with daratumumab-based therapy, including venetoclax and bortezomib (Dara-Ven-Bor). All patients achieved complete remission, with minimal residual disease negativity within four weeks of treatment, allowing them to proceed to allogeneic hematopoietic cell transplantation. The toxicity of the triple schema was acceptable. Our patients and other cases reviewed here suggest that daratumumab combined with venetoclax and bortezomib may be a very effective and relatively safe salvage treatment, even in primary resistant T-ALL. Frontiers Media S.A. 2023-10-24 /pmc/articles/PMC10628456/ /pubmed/37941558 http://dx.doi.org/10.3389/fonc.2023.1228481 Text en Copyright © 2023 Prejzner, Piekoś, Bełdzińska, Sadowska-Klasa, Zarzycka, Bieniaszewska, Lewandowski and Zaucha https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Prejzner, Witold Piekoś, Oliwia Bełdzińska, Karolina Sadowska-Klasa, Alicja Zarzycka, Ewa Bieniaszewska, Maria Lewandowski, Krzysztof Zaucha, Jan Maciej The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review |
title | The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review |
title_full | The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review |
title_fullStr | The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review |
title_full_unstemmed | The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review |
title_short | The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review |
title_sort | role of daratumumab in relapsed/refractory cd38 positive acute leukemias—case report on three cases with a literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628456/ https://www.ncbi.nlm.nih.gov/pubmed/37941558 http://dx.doi.org/10.3389/fonc.2023.1228481 |
work_keys_str_mv | AT prejznerwitold theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT piekosoliwia theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT bełdzinskakarolina theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT sadowskaklasaalicja theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT zarzyckaewa theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT bieniaszewskamaria theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT lewandowskikrzysztof theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT zauchajanmaciej theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT prejznerwitold roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT piekosoliwia roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT bełdzinskakarolina roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT sadowskaklasaalicja roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT zarzyckaewa roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT bieniaszewskamaria roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT lewandowskikrzysztof roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview AT zauchajanmaciej roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview |